Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
CEFTAZIDIME
FRESENIUS KABI CANADA LTD
J01DD02
CEFTAZIDIME
2G
POWDER FOR SOLUTION
CEFTAZIDIME 2G
INTRAVENOUS
11.2ML
Prescription
THIRD GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0116900002; AHFS:
APPROVED
2006-10-05
_ _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CEFTAZIDIME FOR INJECTION, USP 1 g / vial, 2 g / vial, 6 g / vial Sterile Powder for Solution For Intramuscular or Intravenous Use Antibiotic ATC Code: J01DD02 FRESENIUS KABI CANADA LTD. 165 Galaxy Blvd, Suite 100 Toronto, ON M9W 0C8 Date of Initial Authorization: MAR 24, 2015 Date of Revision: FEB 17, 2022 Submission Control Number: 254560 _Product Monograph Master Template _ _ _ _Template Date: September 2020 _ _Ceftazidime for Injection, USP _ _ _ _Page 2 of 45 _ RECENT MAJOR LABEL CHANGES SECTION DATE 1 INDICATIONS [02/2022] 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment [02/2022] 7 WARNINGS AND PRECAUTIONS, Carcinogenesis and Mutagenesis, Sensitivity/Resistance, Skin and Sodium Content [02/2022] 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women [02/2022] TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................................2 TABLE OF CONTENTS ..................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .............................................................................4 1 INDICATIONS ..................................................................................................................4 1.1 Pediatrics ..............................................................................................................5 1.2 Geriatrics ..............................................................................................................5 2 CONTRAINDICATIONS......................................................................................................5 4 DOSAGE AND ADMINISTRATION .......................................................................................5 4.1 Dosing Considerations ............................................... Přečtěte si celý dokument